Donald Trump Sells Repligen Corporation Shares
Donald Trump sold Repligen shares worth between $1,001 and $15,000 on May 22, 2026.
Financial Disclosure Report
United States Congress • Office of Public Records • Washington, DC
Filer Information
- Name:
- Donald J Trump (R)
- Status:
- Member
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Repligen Corporation ($RGEN) | Sell | May 22, 2026 | $1,001 - $15,000 |
Key Points
- Donald Trump sold shares of Repligen Corporation on May 22, 2026, valued between $1,001 and $15,000.
- Repligen, trading at $136.44, has a market cap of $7.70 billion and a forward P/E of 53.6.
- Analysts maintain a 'buy' consensus with a mean price target of $176.11 for Repligen.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On May 22, 2026, Donald Trump, associated with the Republican party, sold shares of Repligen Corporation (NASDAQ: RGEN). The transaction was valued between $1,001 and $15,000 according to a report filed on July 1, 2026. These transactions are part of periodic disclosures under the STOCK Act.
Donald J Trump vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Repligen Corporation Stock Down 22.6%
Shares of Repligen Corporation traded near $136.44 as of Wednesday. The company, which operates in the healthcare sector, specifically in medical instruments and supplies, has a market capitalization of approximately $7.70 billion. It holds a P/E ratio of 149.9 and a forward P/E of 53.6, indicating expectations of future earnings growth. Repligen's stock has seen a 52-week range between $100.99 and $175.77. The company maintains a strong financial position with a current ratio of 9.2 and a quick ratio of 7.5.
$RGEN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Repligen reported revenues of $763.3 million, reflecting a growth rate of 14.8%. The company achieved an earnings per share (EPS) of $0.91, with a net margin of 6.7% and a return on equity (ROE) of 2.5%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at Repligen Corporation
Recent insider activity at Repligen includes a planned sale by CFO Jason Garland, who sold 733 shares at an average price of $145 on June 25, 2026. Conversely, several insiders, including Carrie Eglinton Manner, Nicolas Barthelemy, Martin Madaus, and Glenn Muir, bought shares on May 14, 2026, although the transaction details were not disclosed.
Analysts Set New Price Targets
Analysts continue to show confidence in Repligen. On June 3, 2026, HSBC maintained its 'buy' rating with a price target of $150. Wolfe Research assumed coverage with a 'buy' rating and a $145 target on June 2, 2026. RBC Capital reinstated a 'buy' rating with a $160 target on May 15, 2026. The consensus among 19 analysts is a 'buy' recommendation, with a mean target price of $176.11.
About Repligen Corporation
Repligen Corporation, headquartered in Waltham, Massachusetts, is a life sciences company specializing in bioprocessing technologies and systems. It offers a wide range of products, including chromatography systems, filtration products, and process analytics tools, catering to life sciences, biopharmaceutical, and diagnostics sectors. The company is led by CEO Olivier Loeillot and employs around 2,000 people.
Bottom Line
Donald Trump's sale of Repligen shares is part of routine disclosures required for public officials. Repligen remains a notable player in the healthcare industry, with a strong market position and positive analyst outlook. Investors often track such transactions for insights into potential market movements, though 13F filings and STOCK Act disclosures are backward-looking and may not reflect current positions.
Get Repligen Corporation alerts
New 13F filings, insider trades, and analyst moves on $RGEN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.